Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats

Translational Research

Volumn 151, Issue 4, 2008, Pages 208-216

  Leehey, David J ^a,b   Singh, Ashok K ^c   Bast, Joseph P ^a,b   Sethupathi, Periannan ^b   Singh, Rekha ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME ASSAY; EXPERIMENTAL MODEL; GLOMERULOSCLEROSIS; GLOMERULUS; HISTOPATHOLOGY; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; KIDNEY INJURY; LEAN BODY WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEINURIA; RAT; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES; TISSUE LEVEL; ZUCKER DIABETIC FATTY RAT;

EID: 40849120442     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.01.003     Document Type: Article

References (33)

1. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
2. Andersen S., Tarnow L., Rossing P., Hansen B.V., and Parving H.H. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57 (2000) 601-606
3. Igarashi M., Hirata A., Kadomoto Y., and Tominaga M. Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocr J 53 (2006) 493-501
4. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
5. Lansang M.C., Price D.A., Laffel L.M., et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 59 (2001) 432-438
6. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., and Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77 (1986) 1925-1930
7. Remuzzi A., Perico N., Amuchastegui C.S., et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4 (1993) 40-49
8. Erman A., Veksler S., Gafter U., Boner G., Wittenberg C., and van Dijk D.J. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. J Renin Angiotensin Aldosterone Syst 5 (2004) 146-151
9. Anderson S., Jung F.F., and Inglefinger J.R. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol Renal Fluid Electrolyte Physiol 265 (1993) F477-F486
10. Singh R., Singh A.K., and Leehey D.J. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 288 (2005) F1183-F1190
11. Hoshi S., Shu Y., Yoshida F., et al. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 82 (2002) 25-35
12. Mizuno M., Sada T., Kato M., and Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 25 (2002) 271-278
13. Taniguchi M., Kim S., Zhan Y., and Iwao H. Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. Hypertens Res 25 (2002) 287-294
14. Singh R., Singh A.K., Alavi N., and Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14 (2003) 873-880
15. Vickers C., Hales P., Kaushik V., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277 (2002) 14838-14843
16. Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000) E1-E9
17. Turner A.J., Tipnis S.R., Guy J.L., Rice G., and Hooper N.M. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 80 (2002) 346-353
18. Tikellis C., Johnston C.I., Forbes J.M., et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41 (2003) 392-397
19. Ye M., Wysocki J., William J., Soler M.J., Cokic I., and Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implication for albuminuria in diabetes. J Am Soc Nephrol 17 (2006) 3067-3075
20. Soler M.J., Wysocki J., Ye M., Lloveras J., Kanwar Y., and Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72 (2007) 614-623
21. Wong D.W., Oudit G.Y., Reich H., et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171 (2007) 438-451
22. Kim S.I., Han D.C., and Lee H.B. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 11 (2000) 80-87
23. Gorin Y., Block K., Hernandez J., et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280 (2005) 39616-39626
24. Kagami S., Border W.A., Miller D.E., and Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular mesangial cells. J Clin Invest 93 (1994) 2431-2437
25. Singh R., Alavi N., Singh A.K., and Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48 (1999) 2066-2073
26. Suzaki Y., Ozawa Y., and Kobori H. Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3 (2007) 40-46
27. Sharma R., Sharma M., Reddy S., Savin V.J., Nagaria A.M., and Wiegmann T.B. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci 11 (2006) 968-976
28. Kasiske B.L., O'Donnell M.P., and Keane W.F. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19 suppl 1 (1992) I110-I115
29. Bidani A.K., Picken M., Hacioglu R., Williamson G., and Griffin K.A. Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenic relevance. Am J Physiol Renal Physiol 292 (2007) F647-F654
30. Moriwaki Y., Inokuchi T., Yamamoto A., et al. Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44 (2007) 215-218
31. Kalantarinia K., Awad A.S., and Siragy H.M. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64 (2003) 1208-1213
32. Russo L.M., del Re E.D., Brown D., and Lin H.Y. Evidence for a role of transforming growth factor (TGF)-β1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-β type II receptors. Diabetes 56 (2007) 380-388
33. Zhang S.L., Chen X., Filep J.G., Tang S.S., Ingelfinger J.R., and Chan J.S. Insulin inhibits angiotensinogen gene expression via the mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology 140 (1999) 5285-5292